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Background: The etiology and neurophysiology of generalized pruritus associated with liver disease remain unknown.
Results:Rats with bile duct ligation displayed enhanced scratching and thermal hyperalgesia dependent on PAR2 activation and
TRPV1 potentiation.
Conclusion: Pruritus and hyperalgesia in BDL-rats are associated with neuroinflammation and involve PAR2-induced TRPV1
sensitization.
Significance: Pharmacological modulation of PAR2 and/or TRPV1 emerges as a potential therapeutic approach for liver
pruritus refractory to conventional treatments.
Persistent pruritus is a common disabling dermatologic symp-
tom associated with different etiologic factors. These include pri-
mary skin conditions, as well as neuropathic, psychogenic, or sys-
temic disorders like chronic liver disease. Defective clearance of
potential pruritogenic substances that activate itch-specific neu-
rons innervating the skin is thought to contribute to cholestatic
pruritus. However, because the underlying disease-specific pruri-
togens and itch-specific neuronal pathways andmechanism(s) are
unknown, symptomatic therapeutic intervention often leads to no
or only limited success. In the current study, we aimed to first val-
idate rats with bile duct ligation (BDL) as amodel for hepatic pru-
ritus and then to evaluate the contribution of inflammation,
peripheral neuronal sensitization, and specific signaling pathways
and subpopulations of itch-responsive neurons to scratching
behavior and thermalhypersensitivity.ChronicBDLratsdisplayed
enhanced scratching behavior and thermal hyperalgesia indicative
of peripheral neuroinflammation. BDL-induced itch and hyper-
sensitivity involved a minor contribution of histaminergic/sero-
tonergic receptors, but significant activation of protein-activated
receptor 2 (PAR2) receptors, prostaglandin PGE2 formation, and
potentiation of transient receptor potential vanilloid 1 (TRPV1)
channel activity. The sensitization of dorsal root ganglion nocice-
ptors in BDL ratswas associatedwith increased surface expression
of PAR2 and TRPV1 proteins and an increase in the number of
PAR2- andTRPV1-expressingpeptidergicneurons togetherwith a
shift of TRPV1 receptor expression to medium sized dorsal root
ganglion neurons. These results suggest that pruritus and hyperal-
gesia in chronic cholestatic BDL rats are associated with neuroin-
flammation and involve PAR2-induced TRPV1 sensitization.
Thus,pharmacologicalmodulationofPAR2and/orTRPV1maybe
avaluable therapeutic approach forpatientswithchronic liverpru-
ritus refractory to conventional treatments.
Chronic pruritus is a common, seriously debilitating symp-
tom that can arise from dermatologic disorders, but often also
appears in other disease states as a secondary symptom (1). For
instance, chronic itch has been associated with a wide variety of
pathologies such as malignancy, or hematologic, infectious,
neuropsychiatric, metabolic, and systemic disorders. Patients
with end-stage renal and hepatic diseases often present with
pruritus that might result from diminished renal or hepatic
clearance of pruritogenic substances.
The origin of hepatic pruritus remains poorly understood.
The pathological accumulation of specific pruritogens is
thought to directly or indirectly activate unmyelinated C-fibers
that innervate the skin (2, 3). However, both the identity of
disease-specific pruritogen(s) and the neuronal pathways and
mechanism(s) involved in pruritus are highly controversial. For
instance, although bile salts and other cholephiles are tradition-
ally assumed to be major pruritogens, no correlation exists
between pruritus intensity and either serum biomarkers for
cholestasis or with the course of the disease (1, 4). It is widely
accepted that other substances like the well known pruritogens
histamine and serotonin (5-HT),2 which are released frommast
cells, or endogenous opioids, which are liberated from immune
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cells, may accumulate in hepatic pruritus and activate sensory
neurons (5, 6). Whereas 5-HT and opioid receptor antagonists
have therapeutic potential in a subset of cholestasis patients,
antihistaminics have proven ineffective (7). Recently, increased
serum levels of autotaxin and lysophosphatidic acid (LPA)were
proposed asmediators in human cholestatic pruritus (8–11). In
addition to inducing histamine release from mast cells, LPA
impinges on proinflammatory transcriptional factors, pro-
motes cytokine production and platelet activation (12), and
enhances cytokine-induced COX-2 expression (13). Indeed,
high serum levels of proinflammatory cytokines like IL-31 (14)
or tumor necrosis factor  (TNF-) and interleukin 6 (IL-6),
which are both associated with liver fibrosis (15, 16), might also
contribute to itch.
TRPV1 (transient receptor potential vanilloid 1) is a poly-
modal receptor channel that conducts cations (preferentially
Ca2) in response to either the irritant compound capsaicin or
to extracellular acidic pH and to noxiously high temperatures
(43 °C). Pharmacological and genetic abrogation of TRPV1
function in rodents significantly reduces pain in acute and
chronic inflammatory animalmodels (17, 18).Whereas TRPV1
channel activity is low under normal conditions, mediators
released from injured cells and activated immune cells during
inflammation potentiate TRPV1 activity through activation of
Gprotein-coupled receptors, thereby leading to sensitization of
nociceptive neurons (19).
Besides being a pain sensor, TRPV1may also be an itch inte-
grator of both histaminergic (2, 20) and some nonhistaminergic
pruritogens like serotonin or imiquimod (2, 21). Binding of pru-
ritogens to their receptors, whose identity is often unclear, can
trigger distinct and specific intracellular signaling pathways
that can activate and potentiate TRPV1 function (2, 22). Hence,
TRPV1 may be a common downstream effector in the itch sig-
naling pathway. Indeed,most noxious stimuli can produce pain
and/or itch, depending on how andwhere they are applied (23).
Recently, certain subsets of TRPV1-expressing C-fibers with
specific sensory modalities have been reported to respond dis-
tinctly to different pruritogens like histamine, 5-HT, or chloro-
quine (2, 21, 24). Nevertheless, our understanding of themech-
anisms involved in pruritus signaling by TRPV1-expressing
neurons remains limited.
To our knowledge, no previous study has addressed the neu-
ronal mechanism(s) underlying pruritus associated with chole-
static liver disease, a dynamic and complex condition leading to
inflammation, liver fibrosis, and eventually cirrhosis. We
hypothesized that a Wistar rat model with chronic bile duct
ligation (BDL) (16) may display increased scratching bouts and
provide a model of cholestatic pruritus. We investigated the
involvement of specific pathways and subpopulations of itch-
responsive neurons by pharmacological intervention with
selective antagonists and by immunohistochemistry. In partic-
ular, because neurogenic inflammation in chronic BDL rats (16,
25) may contribute to pruritus through TRPV1 sensitization
(26, 27), we investigated the role of TRPV1 as a final integrator
in the itch signaling pathway.
Here, we show that Wistar BDL rats exhibit augmented
scratching accompanied by peripheral sensitization of primary
afferents as revealed by thermal hyperalgesia. Both symptoms
showed an early onset that correlated with an increase in both
serum biomarkers for cholestasis and proinflammatory cyto-
kines. Whereas histamine/serotonin pathways only play a
minor role in the scratching and thermal hyperalgesia pheno-
type of our rat model, our results demonstrate an involvement
of protease-activated receptor 2 (PAR2) activation, peripheral
inflammation, and TRPV1 potentiation. Hence targeting the
recruitment or modulation of PAR2 or TRPV1 may be useful
therapeutic strategies to treat chronic itch and neuroinflamma-
tion in liver disease patients.
EXPERIMENTAL PROCEDURES
Animals—MaleWistar rats (200–250 g) were obtained from
Charles River, France. Experimental procedures were approved
by the Ethics Committee and met European Union guidelines
for care and management of experimental animals. BDL rats
were operated on as described (16). Control rats were sham-
operated. Behavioral studies started 48 h after surgery and only
when no signs of pain or distress were apparent. Pharmacolog-
ical treatments began 3 weeks after surgery.
Drugs and Reagents—The contribution of different signaling
pathways was assessed by subcutaneous administration of
cyproheptadine (20 mg/kg) (28), intraperitoneal injection of
naloxoneHCl (20mg/kg), gabexatemesylate (10mg/kg, subcu-
taneously), FSLLRY-NH2 (200 g, subcutaneously), ibuprofen
(20 mg/kg, intraperitoneally), meloxicam (1 mg/kg, subcutane-
ously), capsazepine (2 mg/kg, subcutaneously) (29), DD04107
or a lipopeptide containing the scrambled (Scr) sequence of
DD04107 (3 mg/kg, subcutaneously). Drugs were prepared
immediately before use in 0.9% NaCl from a stock solution.
Control groups received the corresponding vehicle. Cyprohep-
tadine, protease, and opioid antagonists were administered 30
min, and other drugs 60 min, before behavioral tests.
All drugs were from Sigma unless otherwise stated. PAR2
agonist (PAR2-AP), a negative retropeptide control (PAR2-RP),
and FSLLRY-NH2 (PAR2-Antg) were from Bachem. Meloxi-
cam (Metacam®) was from Roche Applied Science, gabexate
mesylate was from Tocris (Bristol, UK), and palmitoylated
DD04107 and the scrambled control lipopeptide were synthe-
sized by DiverDrugs (Gavà, Spain).
Primary antibodies used were anti--CGRP (Novus, Little-
ton, CO), anti-PAR2 (Santa Cruz Biotechnology, Santa Cruz,
CA), and anti-TRPV1 (Alomone, Jerusalem, Israel), and NF200
and monoclonal anti--actin (Sigma). Secondary antibodies
were from Jackson (West Grove, PA).
Behavioral Analysis—Rats were acclimatized in a measuring
cage for 30min, followed by videotaping of scratching behavior
for 30 min or 1 h. Spontaneous scratching was quantified by
counting the number of scratches of any region of the body
performed by forepaws or hindpaws.
For Hargreaves’ Plantar Test a standard apparatus (Ugo
Basile, Italy) was used that automatically measured the paw
withdrawal latency (PWL) to a thermal radiant stimulus (30).
To avoid tissue injury in refractory animals, stimulation was
automatically terminated after 32 s. PWL was determined
before and after drug or vehicle treatment in BDL and sham
control rats. Data are presented as mean  S.E. with a mini-
mum of six animals/group.
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Determination of Cholestasis and Inflammation—Serum bil-
irubin, alkaline phosphatase (AP), glutamic oxaloacetic trans-
aminase and glutamic pyruvic transaminase were determined
by standard techniques and prostaglandin PGE2 by ELISA (GE
Healthcare).
Ca2 Imaging in Primary Cultures of Dorsal Root Ganglion
(DRG) Neurons—Primary adult sham and BDL DRG cultures
were established as described (24). Fluorescencemeasurements
were performed after 12 h in vitro in paired BDL and sham
DRG cultures as in Ref. 31. To investigate PAR2 modulation of
TRPV1 activity, cells were exposed for 5 min to PAR2 agonist
(AP), antagonist (Antg), or vehicle, followed by a 10-s pulse
with 100 nM capsaicin (32).
Biotin Labeling of Surface TRPV1 and PAR2 Proteins—Disso-
ciated DRG neurons from sham- and BDL-operated rats were
surface biotinylated with sulfo-NHS-SS-Biotin (Pierce) and
processed as described (33). Biotinylated proteins were isolated
with streptavidin-agarose, resolved by SDS-PAGE, and
detected with the following antibodies and dilutions: TRPV1
(1:1000), PAR2 (1:100), and -actin (1:200). Immunoblots were
digitized and quantified. The absence of contaminating intra-
cellular proteins inmembrane fractions was verified by labeling
of actin.
Immunofluorescent Staining of DRG Neurons and Measure-
ment of Size of Neuronal Somata—Rats were overanesthetized
and then transcardially perfused with saline and then with 4%
paraformaldehyde (pH 7.4). DRGs were quickly removed, post-
fixed, and then placed in sucrose solution. 8-m sections were
co-incubated with anti-TRPV1 (1:1000) and FITC-isolectin B4
(IB4) (1:50) or one of the following antibodies: anti-NF200
(1:1000), anti--CGRP (1:300), anti-GRP (1:500), or anti-PAR2
(1:100) overnight at 4 °C. Cy3- or Alexa Fluor 488-tagged sec-
ondary antibodies were used in 1:200 dilutions for 1 h at 22 °C.
Sections were then washed three times for 10 min in PBS and
mounted. Controls for double-labeling experiments
included imaging with both green and red filters in the pres-
ence of only one primary antibody and/or by omission of all
primary antibodies. Settings for each channel were initially
adjusted to avoid bleeding through. Images were taken on a
Leica DM5000B epifluorescence microscope fitted with a
digital camera. When comparing different samples, identical
settings were used.
The areas of TRPV1-positive (TRPV1) neurons and DRG
neuronal markers were analyzed by tracing the soma perimeter
on a computer screen in a calibrated image and using ImageJ
software (National Institutes of Health, Bethesda, MD). Calcu-
lated areaswere plotted against the percentage of total TRPV1
neurons. More than five sections per animal, three pairs of rats,
and1000 total neurons per phenotype were analyzed.
Statistical Analysis—Results are expressed as mean  S.E.
The nonparametric Mann-WhitneyU-test was used for paired
comparisons. Between groups, one-way ANOVA was followed
by Tukey’s test. Differences were considered significant when
*p 0.1, **p 0.01, and ***p 0.001.
Additional methods and materials are described in supple-
mental Experimental Procedures.
RESULTS
Chronic BDL Rats Displayed Increased Scratching Mediated
by PAR2 Signaling and Neuroinflammation—We evaluated
whether spontaneous scratching behavior was increased in
Wistar BDL rats, an animal model that leads to jaundice,
inflammation, and cirrhosis (16). Cumulative spontaneous
scratching bouts (SSBs) during 1-h observation periods were
recorded in BDL- and sham-operated animals at different time
points. As shown in Fig. 1A, BDL rats exhibited a significant
(2-fold) elevation in the number of SSBs (SSB 59 4, n
12, in BDL comparedwith 39 4, n 8, in sham rats) 48 h after
surgery, a behavior that persisted for at least 3 months. Choles-
tasis was evident from increased serum bilirubin and AP levels,
as well as from elevated levels of hepatic injury markers glu-
tamic oxaloacetic transaminase and glutamic pyruvic transam-
inase (Table 1). Similarly, proinflammatory IL-6was elevated in
BDL sera, as shown previously (16).
To determine the involvement of different molecular path-
ways in enhanced scratching, we first administered the mixed
histaminergic/serotonergic antagonist cyproheptadine. This
procedure slightly decreased SSBs in BDL rats (SSBs 66 4
comparedwith 94 5with vehicle, n 7) (Fig. 1B). In contrast,
scratching bouts were markedly reduced when BDL rats were
treated with the systemic opioid receptor antagonist naloxone
HCl (NalHCl) (SSB 22 5 versus 84 6 with saline, n 7)
(Fig. 1B).
Besides histamine and endogenous opioids (33), also tryp-
tase, chimase, and other proteases are released during inflam-
mation by immune cells (34). To assess the involvement of pro-
teases in the scratching behavior, we administered the specific
lima bean trypsin inhibitor, the serine protease inhibitor gabex-
ate mesylate, and the PAR2 receptor antagonist, FSLLRY-NH2
intoBDL- and sham-operated rats. Importantly, all three antag-
onists produced a marked decrease in scratching behavior.
Thus, for instance, the lima bean trypsin inhibitor reduced the
SSBs in BDL rats to 38 7 (compared with 86 10 with saline
(n 7) (data not shown)). Similarly, as illustrated in Fig. 1C, the
serine protease inhibitor gabexate mesylate reduced SSBs to
16 1 compared with 89 2 with saline injection (n 7), and
the PAR2 antagonist FSLLRY-NH2 diminished SSBs to 38 11
versus 85  4 with saline treatment (n  7). Because all three
inhibitors are predicted to prevent activation of PAR2, the
scratching behavior in BDL rats may be mediated, at least in
part, by PAR2 activation.
Chronic BDL Rats Display Increased Thermal Hyperalgesia—
Primary afferents responding to serotonin and PAR2 activation
are polymodal C-fibers that also respond to noxious stimuli like
mustard oil and capsaicin (34).Moreover, PAR2 has been impli-
cated in both pruritus (3, 28, 34–36) and hyperalgesia (37, 38).
We therefore asked whether hepatic pruritus in Wistar BDL
rats might be accompanied by altered nociceptive thermal
responses. Indeed, the PWL from a hot source was significantly
shorter in BDL rats than in control animals. For instance, 3
weeks after surgery, the PWL in BDL rats was reduced to 9.0
0.4 s (n 21) compared with 15.6 0.5 s in controls (n 19).
The thermal hypersensitivity in BDL rats remained constantly
increased over the time of our analysis (Fig. 2A).
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We next evaluated the role of histamine/serotonin, endoge-
nous opioids, and protease pathways on thermal hypersensitiv-
ity. Whereas the histaminergic/serotonergic antagonist cypro-
heptadine did not interfere with the withdrawal latency in
Wistar chronic BDL rats, a single dose of NalHCl or of the
protease inhibitors gabexate methylate or of PAR2-Antg signif-
icantly attenuated BDL thermal hyperalgesia (Fig. 2, B and C).
Interestingly, administration of either gabexate mesylate or of
PAR2-Antg reverted PWL values close to those of control rats.
PAR2 activation triggers inflammatory responses through
PLA2 activation and arachidonic acid release (39).We therefore
used ibuprofen, a COX-1/COX-2 inhibitor, and the preferen-
tial COX-2 inhibitor meloxicam (data not shown) to analyze
the role of eicosanoids in the itch response. Ibuprofen admin-
istration reduced scratching bouts by approximately 50% (Fig.
3A). Furthermore, as expected, heat hypersensitivity in BDL
rats was reversed both by ibuprofen (Fig. 3B) and by the selec-
tive COX-2 antagonist meloxicam (data not shown). Impor-
tantly, the ibuprofen-induced change in serum levels of PGE2
correlated remarkably well with the observed behavioral index
(Fig. 3, A and C). These experiments therefore suggest that
prostanoids are involved in liver disease-associated pruritus
and that thermal hyperalgesia in chronic BDL rats is mostly
mediated by a PAR2 signaling pathway.
TRPV1Contributes to Itch andThermalHyperalgesia in BDL
Rats—Because activated PAR2 may modulate neurogenic
inflammation and increase nociceptor excitability by potentiat-
ing TRPV1 activity (40), we determined the contribution of
TRPV1 sensitization to pruritus. Systemic administration of
theTRPV1 antagonist capsazepine to BDL- and sham-operated
rats produced a significant attenuation in SSBs in BDL, but not
in control rats (BDL: SSB  21  2 compared with 86  5 in
vehicle, n  6; sham-operated: SSB  47  5 compared with
46  5 in vehicle, n  6) (Fig. 4A). Likewise, capsazepine
blocked thermal hyperalgesia in chronic BDL rats (PWL 
17.3 0.6 s compared with 10.7 0.7 s in vehicle-treated BDL
rats, n 9) (Fig. 4B).
Enhanced TRPV1 activity may arise either from increased
intrinsic channel activity and/or from enhanced plasma mem-
brane expression (19, 40). To assess whether regulated exocy-
totic plasma membrane insertion of TRPV1 contributed to the
inflammatory sensitization of TRPV1 in BDL rats, we evaluated
the antinociceptive and antipruritic activities of DD04107, a
lipopeptide known to interfere with vesicle fusion in nocicep-
tors (40). It is based on SNAP25 peptide sequence and is
thought to compete with SNAP25 for its incorporation into a
SNARE complex that is needed for exocytosis in neurons. As
illustrated in Fig. 4A, systemic administration of DD04107 sig-
nificantly decreased the scratching bouts in BDL rats compared
with the administration of a lipopeptide containing the scram-
bledDD04107 sequence (Scr) (SSBs 20 4 versus 73 8,n
6, respectively). Similarly, DD04107 selectively attenuated the
thermal hypersensitivity in chronic BDL rats (Fig. 4B). Hence,
recruitment of TRPV1 to the membrane of nociceptor termi-
FIGURE 1. Effect of the blockade of histamine/serotonin-, opioid-, prote-
ase-, andPAR2-activatedpathways in the enhanced scratchingbehavior
of a ratmodel with BDL. A, time course of cumulative spontaneous scratch-
ing bouts/h in BDL (●) and sham-operated (E) control rats after surgery (n
8–12). B, effect of the mixed His/5-HT antagonist cyproheptadine (Cypr) and
the systemic opioid antagonist naloxone HCl (NalHCl) on the spontaneous
scratching bouts/h. Sh, sham. C, spontaneous scratching bouts after admin-
istration of the protease inhibitor gabexate mesylate (GabexMes) and PAR2
antagonist (PAR2-Antg) recorded during the first 30 min. V, vehicle; T, treat-
ment. n 6–9 animals. Each data point represents mean S.E. (error bars).
*, p 0.0; **, p 0.01; ***, p 0.001, Mann-Whitney U-test).
TABLE 1
Serum biomarkers of bilirubin (BR), alkaline phosphatase (AP), glu-
tamic oxaloacetic transaminase (GOT), and glutamic pyruvic transam-
inase (GPT) obtained 7 days after surgery
Results are expressed as mean  S.E. with (**p  0.01, n  5, Mann-Whitney
U-test).
Groups BR AP GOT GPT
mg/dl units/liter units/liter units/liter
Sham 0.14 0.01 601.5 59.5 84.8 4.4 57.4 1.2
BDL 6.43 1.35** 1018 46.6** 210.7 27.2** 109.5 14.3**
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nals likely contributes importantly to enhanced scratching
behavior in BDL rats.
Acutely Dissociated DRG Neurons from BDL Rats Display
PAR2 Up-regulation and Increased TRPV1 Activity—Because
pharmacological inhibition of PAR2 and TRPV1 significantly
reduced scratching and thermal hyperalgesia in BDL rats, we
asked whether altered PAR2 and/or TRPV1 function might be
detected in acutely dissociatedDRGneurons fromBDL rats. To
prevent serial dilution of proinflammatory substances, cells
were only cultured for approximately 12 h, with no change in
culture medium. Paired nociceptor cultures from BDL- and
sham-operated rats were tested by exposing them for 5 min to
either vehicle (Veh), 100 M PAR2 agonist (AP), or antagonist
(Antg), always followed by a test pulse of the TRPV1 agonist
capsaicin (100 nM). Because the TRPV1 channel is highly per-
meable to Ca2, we used the ratiometric Ca2-sensitive indica-
tor dye Fura-2 to assess capsaicin responses. As shown in Fig. 5,
under control (Veh) conditions, BDL DRG neurons displayed
both significantly increasedmagnitudes of individual responses
(Fig. 5,A and B) and a larger percentage of responding neurons
FIGURE 2. Effect of the blockade of histamine/serotonin-, opioid-, prote-
ase-, and PAR2-activated pathways on the increased thermal hyperalge-
sia in a ratmodelwith BDL.A, time course of pawwithdrawal latency froma
heat source in BDL (●) and sham (Sh)-operated (E) control rats after surgery
(n 8–12). B and C, effect of the mixed His/5-HT antagonist cyproheptadine
(Cypr) and the systemic opioid antagonist naloxone HCl (NalHCl) (B) and of
the protease inhibitor gabexate mesylate (GabexMes) and PAR2 antagonist
(PAR2-Antg) on thermal sensitivity. V, vehicle; T, treatment. n 6–9 animals.
Each data point represents mean S.E. (error bars). *, p 0.1; ***, p 0.001,
Mann-Whitney U-test).
FIGURE 3. Role of COX-1/COX-2 in spontaneous scratching and thermal
hyperalgesia in BDL rats. A and B, time course of scratching bouts/h (A) and
of the pawwithdrawal latency from a heat source of BDL and sham-operated
rats (B). Vehicle controls and animals treated with a single dose (20 mg/kg,
intraperitoneally) of the COX-1/COX-2 inhibitor ibuprofen (Ibu) are com-
pared. C, serum PGE2 levels after the single ibuprofen administration in both
BDL- and sham-operated rats. Each point represents the mean  S.E. (error
bars) of n 6.
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(Fig. 5C). Interestingly, previous activation of PAR2 with
PAR2-APproduced a2-fold increase in the percentage of cap-
saicin-responsive neurons in sham cultures, reaching a level
that was close to that observed with vehicle in BDL neurons
(Fig. 5C). Hence, even when inflammatory agentsmight be par-
tially or completely diluted, BDL DRG nociceptors appeared
submaximally activated, suggesting a long lasting modification
of TRPV1 activity. As negative control, PAR2-RP had no effect.
Moreover, PAR2 receptor silencing by transfection of paired
BDL and control neurons with a specific PAR2 small interfering
RNA (siRNA), previously shown to strongly reduce PAR2 pro-
tein levels in nociceptor cultures, significantly produced con-
comitant reduced capsaicin responses in both types of cultures
(supplemental Fig. 1, A–D). The augmented PAR2 activity in
BDL DRGs was associated with an increase in PAR2 receptor
immunoreactivity in DRGs (Fig. 6A) and an2-fold enhanced
recruitment of PAR2 receptors to the plasma membrane as
revealed by immunodetection of surface biotinylated fractions
(Fig. 6B). Altogether, these results indicate that nociceptors of
BDL rats are sensitized by increased PAR2 signaling.
To better characterize TRPV1 potentiation in BDL rats, we
evaluated the average magnitude of Ca2 influx and the per-
centage of responding nociceptors from paired BDL and sham
DRG cultures at different agonist concentrations (from 1 nM to
5 M capsaicin). Over the entire concentration range, TRPV1-
mediated Ca2 influx into BDL neurons was increased approx-
imately 2-fold compared with controls (Fig. 5, D and E). The
half-maximal effective capsaicin concentration (EC50) for evok-
ing intracellular [Ca2] increases was 12  2 nM in BDL neu-
rons versus 360  30 nM for sham cultures. A transcription-
independent, 2-fold increase in TRPV1 protein levels was
observed in DRG homogenates from BDL rats compared with
controls (supplemental Fig. 2). Importantly, similar to
enhanced PAR2 surface expression in BDL nociceptors, a sig-
nificant translocation of TRPV1 receptor channels to the
plasma membrane was found by surface protein biotinylation
(Fig. 6B). These data were further confirmed by immunocyto-
chemistry of nonpermeabilized live BDL and sham neurons
using a TRPV1 antibody that recognizes an extracellular
epitope (supplemental Fig. 3). The percentage of capsaicin-re-
sponsive neurons was also notably higher in BDLDRG cultures
(Fig. 5F). Thus, whereas40% of sham neurons were activated
by 1Mcapsaicin, this percentage increased up to80% inBDL
cultures. These results were bolstered by immunohistochemis-
try that revealed a robust increase in the number of TRPV1-
expressing neurons in BDL DRG sections (Fig. 6A).
We next examined whether the increased percentage of cap-
saicin-responsive neurons correlated with a shift of TRPV1
expression to a specific DRG subpopulation. DRG cryosections
were co-labeled for TRPV1 and CGRP or IB4, two markers
commonly used to identify peptidergic and nonpeptidergic
C-fibers, respectively, and for neurofilament NF200 to identify
medium and large size myelinated A-fibers. Fig. 6C displays
examples of DRG sections from control and BDL rats (left
and right panels, respectively) labeled for TRPV1 (red) and
different DRG markers (green), and double-labeled neurons
(yellow). Remarkably, whereas the percentage of cells immu-
noreactive to TRPV1 and IB4 remained unaltered, the pro-
portion of peptidergic neurons co-expressing TRPV1 and
CGRP (TRPV1CGRP) was significantly increased in BDL
rats (36.7  4.5% compared with 25.4  3.9% in sham con-
trol, *p  0.1).
Agreeing with previous work (37), area histograms showed
that TRPV1 was expressed mainly in small diameter neurons.
TRPV1CGRP neurons clustered in the smaller group (areas
600 m2). Notably, the number of TRPV1CGRP was sig-
nificantly increased in BDL rats (Fig. 6, C and D). A second
major difference was noticed within medium sized neurons
(800–1200 m2) (Fig. 6E), which probably correspond to
somata of A-fibers. The percentage of TRPV1NF200 neu-
rons was increased approximately 3-fold in BDL rats compared
with sham-operated rats (20  5 and 6  2%, respectively).
Taken together, these findings indicate that both an up-regula-
tion of PAR2 and TRPV1 protein expression in nociceptors as
well as a potentiation of their activity underlie the scratching
behavior observed in this model of chronic liver disease.
DISCUSSION
In this study, we have established an animal model for pruri-
tus associated with cholestasis. Our work suggests that hista-
FIGURE 4. Enhanced pruritus and thermal hyperalgesia in BDL rats is
attenuated by TRPV1 inhibition and by blockade of TRPV1 membrane
translocation. A and B, effect on spontaneous scratching bouts/h (A) and on
paw withdrawal latency from a heat source (B) of the selective TRPV1-inhibi-
tor capsazepin (CPZ) or theexocytosis blockerDD04107.V, vehicle; Scr, scram-
bled sequence of peptide DD04107; T, treatment. n 9. Each data point rep-
resents mean  S.E. (error bars). *, p  0.1; ***, p  0.001, Mann-Whitney
U-test).
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mine/serotonin pathways play only aminor role in hepatic pru-
ritogenesis. By contrast, stimulation of PAR2 receptors, which
might be activated by mast cell tryptase released in inflamma-
tory processes, leads to the potentiation of the capsaicinTRPV1
receptor channel activity. This activation, which also leads to
thermal hyperalgesia, involves several mechanisms, including
increased cellular expression, plasmamembrane residence, and
intrinsic channel activity.
We used a model of cholestatic liver fibrosis based on bile
duct ligation inWistar rats, a procedure that eventually leads to
cirrhosis and to hepatic encephalopathy (16, 25, 41). We found
that BDL rats display increased spontaneous scratching indic-
ative of itch, a common dermatologic symptom in chronic liver
disease. Increased scratching emerged shortly after surgery and
lasted for up to 3 months, the latest time point investigated.
Unlike previous models of acute cholestasis by bile duct resec-
tion in rodents that display decreased nociception (5, 42), our
model resulted in increased thermal hyperalgesia. This differ-
ence cannot be accounted for by differences in the duration of
cholestasis, as we observed thermal hyperalgesia already 48 h
after surgery. However, differences between rat strains in noci-
ception thresholds (43, 44) could well account for these differ-
ences. Importantly, our observation of thermal hyperalgesia in
BDL rats perfectly fits to the up-regulation and sensitization of
the heat-sensitive TRPV1 channel which we have demon-
strated in this work.
Patients with cholestasis and itch display signs of peripheral
neuroinflammation as reflected by increased numbers of der-
FIGURE 5. PAR2 sensitizes TRPV1 in BDL nociceptors. A, representative traces of changes in Fura-2 fluorescence indicative of Ca
2 influx upon a 0.1 M
capsaicin (0.1 Caps) pulse, expressed in arbitrary units (a.u.), in sham (black) or BDL (red) nociceptors exposed to PAR2-Antg (dashed line) or vehicle (solid trace).
All neurons show a typical Ca2 rise in response to raising extracellular [K] to 40 mM. Neurons from sham-operated controls produced smaller capsaicin
responses than those from BDL rats. PAR2 inhibition (PAR2-Antg) suppressed capsaicin responses in BDL neurons more strongly than in control neurons. B,
mean Fura-2 fluorescence changes induced by 0.1 capsaicin obtained as in A following different PAR2 treatments in BDL and sham nociceptors. Veh, vehicle;
Antg, PAR2-Antg; AP, PAR2-activating peptide; and RP, a retroactive peptide as a negative control. C, percentage of K
-responsive neurons that also react to
capsaicin at 0.1M.n (paired cultures)3.D, representative traces of capsaicin-inducedCa2 responses as reportedbyFura-2 fluorescence at different agonist
concentrations in BDL neurons (solid trace) compared with sham neurons (dashed line). E, mean peak Fura-2 fluorescence magnitude obtained as in D with
different capsaicin concentrations inBDLand shamnociceptor cultures (blackandwhite columns, respectively). F, proportionof capsaicin-responsive shamand
BDL neurons in culture at different capsaicin concentrations. Each data point represents mean S.E. (error bars); n.s., nonsignificance; *, p 0.1; **, p 0.01;
***, p 0.001, Mann-Whitney U-test).
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mal mast cells (45). Furthermore, increased mast cell degranu-
lation has been reported in animals with chronic biliary
obstruction (46). However, despite intensive investigation, the
mediators and neuronal mechanisms involved in cholestatic
pruritus remain still unresolved. Recently, autaxin and LPA lev-
els have been correlated with itch intensity in cholestatic
patients (47). LPA induces histamine release from mast cells
(48). However, histamine seems to play only a minor role in
cholestatic pruritus both in patients (49) and in our rat model.
On the other hand, autaxin is highly expressed in submucosal
mast cells also containing chimase and tryptase (50). Tryptase
and other proteases, released during mast cell degranulation,
not only serve to cleave many substrates involved in inflamma-
tion and wound repair, but also potently activate protease-ac-
tivated PAR2 receptors (51). Indeed, we found a significant
activation of PAR2 receptors, enhanced downstream PGE2
formation, and potentiation of TRPV1 channel activity. DRG
nociceptors in BDL rats displayed increased overall expres-
sion of PAR2 and TRPV1 proteins, an increased number of
PAR2- and TRPV1-expressing peptidergic neurons, and a
shift of TRPV1 receptor expression to medium sized DRG
neurons. This changed pattern of TRPV1 expression has
been found in animal models of hyperalgesia associated with
acute and chronic inflammation (52, 53), supporting our
FIGURE 6.Changes in PAR2 and TRPV1protein expression induced in BDL rats. A, representativemerged images from immunohistochemical detection of
TRPV1 (red), PAR2 (green), and overlay (yellow) in sham (left) and BDL DRG sections (right). The number of cells expressing both TRPV1 and PAR2 was robustly
increased in BDL rats. B, representativeWestern blots of TRPV1 andPAR2 protein in plasmamembrane and cytosolic fractions from shamandBDLDRG cultures
obtained by cell surface biotinylation. Optical band densities were analyzed and normalized to cytosolic -actin (right). Averages from four independent
experiments are shown. C, merged images showing red-labeled TRPV1 together with CGRP (top), IB4 (middle), or NF200 (bottom) labeled in green. Co-localiza-
tion results are in yellow. Scale bars, 50m.D and E, area frequency distribution of TRPV1CGRP and TRPV1NF200neurons, respectively.N (pairs) 3. Each
data point represents mean S.E. (error bars; n.s., nonsignificance; *, p 0.1, Mann-Whitney U-test).
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conclusion that inflammation plays an important role in
cholestatic pruritus.
Protease- and PAR2-mediated signaling pathways have been
implicated in neurogenic inflammation, in certain types of gen-
eralized pruritus (28, 54), and also in hyperalgesia (37, 38).
Notably, patients refer cholestatic pruritus as an irritation that
cannot be relieved by scratching (4), a sensation that could be
well accounted for by peripheral neuronal sensitization. An
activation of the Mas-related G protein-coupled receptor
MgrprC11, rather than of PAR2, was recently proposed as
underlying the scratching behavior elicited by PAR2-AP agonist
or trypsin administration (24). On the other hand, mucunain,
the active ingredient of cowhage, is known to induce itch and a
burning sensation through activation of PAR2 and PAR4 (55).
Moreover, other reports stressed a pivotal role of PAR2 in skin
conditions such as in dry-skin itch (35) and in atopic dermatitis
(56, 57). The importance of PAR2 activation in our model was
confirmed not only pharmacologically by antagonist adminis-
tration, but also by specific silencing of the PAR2 receptor in
primary BDL nociceptor cultures.
PAR2 activation has been reported to modulate the expres-
sion and ion channel activity of TRPV1 (37, 38). We therefore
evaluated the magnitude of TRPV1 activity and its modulation
by PAR2 in nociceptor cultures. Under basal conditions, both
the percentage of capsaicin-responding neurons and the indi-
vidual cellular response to the TRPV1 agonist capsaicin were
4-fold higher in BDL nociceptors. TRPV1 sensitization by
PAR2 activation appeared to reach near maximal levels in BDL
rats, because the percentage of TRPV1 neurons derived from
those rats was not further increased when challenged with
PAR2 agonist. These results suggest an up-regulation of PAR2
signaling in BDL nociceptors whichwas corroborated byWest-
ern blotting and immunohistochemistry.
Although TRPV1 protein levels in BDL nociceptors were
only increased 2-fold, the TRPV1 channel activity elicited by
the agonist capsaicin was increased approximately 30-fold. In
addition to increasing transcription and/or translation, proin-
flammatory stimuli can sensitize TRPV1 by several additional
mechanisms that either lead to a fast, acute decrease of the
activation threshold by receptor phosphorylation or to an
increased residence of the protein at the cell surface. The func-
tional coupling of PAR2 to TRPV1 through PKC- and PKA-
mediated phosphorylation of TRPV1 has been well docu-
mented (38). The effect of an in vivo application of an inhibitor
previously demonstrated to block regulated exocytosis of
TRPV1 in DRG nociceptor cultures (19, 40) now suggested an
important contribution of increased plasma membrane inser-
tion of TRPV1 in the genesis of both pruritus and thermal
hyperalgesia.
In summary, our work indicates that activation of PAR2 sig-
naling, presumably by inflammatory release of proteases from
cutaneous mast cells found in close proximity to nerve termi-
nals, sensitizes nociceptors by augmenting the expression and
activity of neuronal TRPV1 channels. The presence of addi-
tional proinflammatory mediators like autaxin, LPA, IL-6,
PGE2, and TNFmay further enhance nociceptor sensitization
and/or mast cell degranulation, thus contributing to the per-
sistence of a pruritogenic state. PAR2 receptors and TRPV1
channels may be interesting therapeutic targets for developing
compounds that attenuate chronic systemic pruritus arising
from liver disease or possibly from other systemic disorders.
Acknowledgments—We thank Drs. F. J. Rodríguez-Jiménez and V.
Moreno-Manzano (Centro de Investigación Principe Felipe) for help
with quantitative RT-PCR experiments.
REFERENCES
1. Weisshaar, E., Kucenic, M. J., and Fleischer, A. B., Jr. (2003) Pruritus: a
review. Acta Derm. Venereol. Suppl. 213, 5–32
2. Imamachi, N., Park, G. H., Lee, H., Anderson, D. J., Simon,M. I., Basbaum,
A. I., and Han, S. K. (2009) TRPV1-expressing primary afferents generate
behavioral responses to pruritogens via multiple mechanisms. Proc. Natl.
Acad. Sci. U.S.A. 106, 11330–11335
3. Steinhoff, M., Neisius, U., Ikoma, A., Fartasch, M., Heyer, G., Skov, P. S.,
Luger, T. A., and Schmelz, M. (2003) Proteinase-activated receptor-2 me-
diates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23,
6176–6180
4. Bergasa, N. V., Mehlman, J. K., and Jones, E. A. (2000) Pruritus and fatigue
in primary biliary cirrhosis. Baillieres Best Pract. Res. Clin. Gastroenterol.
14, 643–655
5. Nelson, L., Vergnolle, N., D’Mello, C., Chapman, K., Le, T., and Swain,
M. G. (2006) Endogenous opioid-mediated antinociception in cholestatic
mice is peripherally, not centrally, mediated. J. Hepatol. 44, 1141–1149
6. Weisshaar, E., Ziethen, B., Röhl, F. W., and Gollnick, H. (1999) The anti-
pruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent
on mast cell depletion: an experimental study. Exp. Dermatol. 8, 254–260
7. Glasova, H., and Beuers, U. (2002) Extrahepatic manifestations of choles-
tasis. J. Gastroenterol. Hepatol. 17, 938–948
8. Kremer, A. E.,Martens, J. J., Kulik,W., Ruëff, F., Kuiper, E.M., van Buuren,
H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., Geenes,
V. L., Williamson, C., Moolenaar, W. H., Beuers, U., and Oude Elferink,
R. P. (2010) Lysophosphatidic acid is a potential mediator of cholestatic
pruritus. Gastroenterology 139, 1008–1018
9. Kremer, A. E., Martens, J. J., Kulik,W.,Williamson, C., Moolenaar,W. H.,
Kondrackiene, J., Beuers, U., and Elferink, R. P. J. O. (2009) Identification
of lysophosphatidic acid as neural activator in blood of pruritic cholestatic
patients. Acta Derm-Venereol. 89, 702
10. Kremer, A. E., Martens, J. J., Kulik,W.,Williamson, C., Moolenaar,W. H.,
Kondrackiene, J., Beuers, U., and Elferink, R. P. J. O. (2010) Autotaxin but
not bile salts correlate with itch intensity in cholestasis. J. Hepatol. 52, S1
11. Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M., Met-
tang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J.,
Davies, N. A., Rust, C., Engert, A., Jalan, R., Oude Elferink, R. P., Beuers, U.
(2012) Serum autotaxin is increased in pruritus of cholestasis, but not of
other origin, and responds to therapeutic interventions. Hepatology 56,
1391–1400
12. vanMeeteren, L. A., andMoolenaar, W. H. (2007) Regulation and biolog-
ical activities of the autotaxin-LPA axis. Prog. Lipid Res. 46, 145–160
13. Nochi, H., Tomura, H., Tobo, M., Tanaka, N., Sato, K., Shinozaki, T.,
Kobayashi, T., Takagishi, K., Ohta, H., Okajima, F., and Tamoto, K. (2008)
Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction
by synovial fluid of patients with rheumatoid arthritis in fibroblast-like
synovial cells. J. Immunol. 181, 5111–5119
14. Takaoka, A., Arai, I., Sugimoto, M., Honma, Y., Futaki, N., Nakamura, A.,
and Nakaike, S. (2006) Involvement of IL-31 on scratching behavior in
NC/Nga mice with atopic-like dermatitis. Exp. Dermatol. 15, 161–167
15. Barak, V., Selmi, C., Schlesinger, M., Blank, M., Agmon-Levin, N., Kalick-
man, I., Gershwin, M. E., and Shoenfeld, Y. (2009) Serum inflammatory
cytokines, complement components, and soluble interleukin 2 receptor in
primary biliary cirrhosis. J. Autoimmun. 33, 178–182
16. Jover, R., Rodrigo, R., Felipo, V., Insausti, R., Sáez-Valero, J., García-Ayl-
lón,M. S., Suárez, I., Candela, A., Compañ, A., Esteban, A., Cauli, O., Ausó,
E., Rodríguez, E., Gutiérrez, A., Girona, E., Erceg, S., Berbel, P., and Pérez-
Mateo, M. (2006) Brain edema and inflammatory activation in bile duct
TRPV1 in Cholestatic Pruritus
APRIL 5, 2013•VOLUME 288•NUMBER 14 JOURNAL OF BIOLOGICAL CHEMISTRY 9683
ligated rats with diet-induced hyperammonemia: a model of hepatic en-
cephalopathy in cirrhosis. Hepatology 43, 1257–1266
17. García-Martinez, C., Humet, M., Planells-Cases, R., Gomis, A., Caprini,
M., Viana, F., De La Pena, E., Sanchez-Baeza, F., Carbonell, T., De Felipe,
C., Pérez-Paya, E., Belmonte, C., Messeguer, A., and Ferrer-Montiel, A.
(2002) Attenuation of thermal nociception and hyperalgesia by VR1
blockers. Proc. Natl. Acad. Sci. U.S.A. 99, 2374–2379
18. Caterina, M. J., and Julius, D. (2001) The vanilloid receptor: a molecular
gateway to the pain pathway. Annu. Rev. Neurosci. 24, 487–517
19. Planells-Cases, R., Garcìa-Sanz, N., Morenilla-Palao, C., and Ferrer-Mon-
tiel, A. (2005) Functional aspects andmechanisms of TRPV1 involvement
in neurogenic inflammation that leads to thermal hyperalgesia. Pflugers
Arch. 451, 151–159
20. Shim,W. S., Tak,M.H., Lee,M.H., Kim,M., Kim,M., Koo, J. Y., Lee, C.H.,
Kim, M., and Oh, U. (2007) TRPV1 mediates histamine-induced itching
via the activation of phospholipase A2 and 12-lipoxygenase. J. Neurosci.
27, 2331–2337
21. Kim, S. J., Park, G. H., Kim, D., Lee, J., Min, H., Wall, E., Lee, C. J., Simon,
M. I., Lee, S. J., and Han, S. K. (2011) Analysis of cellular and behavioral
responses to imiquimod reveals a unique itch pathway in transient recep-
tor potential vanilloid 1 (TRPV1)-expressing neurons. Proc. Natl. Acad.
Sci. U.S.A. 108, 3371–3376
22. Bíró, T., Tóth, B. I., Marincsák, R., Dobrosi, N., Géczy, T., and Paus, R.
(2007) TRP channels as novel players in the pathogenesis and therapy of
itch. Biochim. Biophys. Acta 1772, 1004–1021
23. Ross, S. E. (2011) Pain and itch: insights into the neural circuits of aversive
somatosensation in health and disease. Curr. Opin. Neurobiol. 21,
880–887
24. Liu, Q.,Weng, H. J., Patel, K. N., Tang, Z., Bai, H., Steinhoff,M., andDong,
X. (2011) The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch
and hyperalgesia. Sci. Signal. 4, ra45
25. Montoliu, C., Piedrafita, B., Serra, M. A., del Olmo, J. A., Urios, A., Ro-
drigo, J.M., and Felipo, V. (2009) IL-6 and IL-18 in bloodmay discriminate
cirrhotic patients with and without minimal hepatic encephalopathy.
J. Clin. Gastroenterol. 43, 272–279
26. Seeliger, S., Derian, C. K., Vergnolle, N., Bunnett, N. W., Nawroth, R.,
Schmelz, M., Von DerWeid, P. Y., Buddenkotte, J., Sunderkötter, C., Me-
tze, D., Andrade-Gordon, P., Harms, E., Vestweber, D., Luger, T. A., and
Steinhoff, M. (2003) Proinflammatory role of proteinase-activated recep-
tor 2 in humans and mice during cutaneous inflammation in vivo. FASEB
J. 17, 1871–1885
27. Namer, B., Carr, R., Johanek, L. M., Schmelz, M., Handwerker, H. O., and
Ringkamp, M. (2008) Separate peripheral pathways for pruritus in man.
J. Neurophysiol. 100, 2062–2069
28. Costa, R., Marotta, D. M., Manjavachi, M. N., Fernandes, E. S., Lima-
Garcia, J. F., Paszcuk, A. F., Quintão, N. L., Juliano, L., Brain, S. D., and
Calixto, J. B. (2008) Evidence for the role of neurogenic inflammation
components in trypsin-elicited scratching behaviour in mice. Br. J. Phar-
macol. 154, 1094–1103
29. Perkins, M. N., and Campbell, E. A. (1992) Capsazepine reversal of the
antinociceptive action of capsaicin in vivo. Br J. Pharmacol. 107, 329–333
30. Hargreaves, K., Dubner, R., Brown, F., Flores, C., and Joris, J. (1988) A new
and sensitive method for measuring thermal nociception in cutaneous
hyperalgesia. Pain 32, 77–88
31. Lainez, S., Valente, P., Ontoria-Oviedo, I., Estévez-Herrera, J., Camprubí-
Robles, M., Ferrer-Montiel, A., and Planells-Cases, R. (2010) GABAA re-
ceptor-associated protein (GABARAP)modulates TRPV1 expression and
channel function and desensitization. FASEB J. 24, 1958–1970
32. Amadesi, S., Cottrell, G. S., Divino, L., Chapman, K., Grady, E. F., Bautista,
F., Karanjia, R., Barajas-Lopez, C., Vanner, S., Vergnolle, N., and Bunnett,
N. W. (2006) Protease-activated receptor 2 sensitizes TRPV1 by protein
kinase C- and A-dependentmechanisms in rats andmice. J. Physiol. 575,
555–571
33. Sanz-Salvador, L., Andrés-Borderia, A., Ferrer-Montiel, A., and Planells-
Cases, R. (2012) Agonist- and Ca2-dependent desensitization of TRPV1
channel targets the receptor to lysosomes for degradation. J. Biol. Chem.
287, 19462–19471
34. Akiyama, T., Merrill, A. W., Carstens, M. I., and Carstens, E. (2009) Acti-
vation of superficial dorsal horn neurons in the mouse by a PAR2 agonist
and 5-HT: potential role in itch. J. Neurosci. 29, 6691–6699
35. Akiyama, T., Merrill, A. W., Zanotto, K., Carstens, M. I., and Carstens, E.
(2009) Scratching behavior and Fos expression in superficial dorsal horn
elicited by protease-activated receptor agonists and other itch mediators
in mice. J. Pharmacol. Exp. Ther. 329, 945–951
36. Tsujii, K., Andoh, T., Ui, H., Lee, J. B., and Kuraishi, Y. (2009) Involvement
of tryptase and proteinase-activated receptor 2 in spontaneous itch-asso-
ciated response in mice with atopy-like dermatitis. J. Pharmacol. Sci. 109,
388–395
37. Amadesi, S., Nie, J., Vergnolle, N., Cottrell, G. S., Grady, E. F., Trevisani,
M.,Manni, C., Geppetti, P.,McRoberts, J. A., Ennes, H., Davis, J. B.,Mayer,
E. A., and Bunnett, N. W. (2004) Protease-activated receptor 2 sensitizes
the capsaicin receptor transient receptor potential vanilloid receptor 1 to
induce hyperalgesia. J. Neurosci. 24, 4300–4312
38. Dai, Y., Moriyama, T., Higashi, T., Togashi, K., Kobayashi, K., Yamanaka,
H., Tominaga, M., and Noguchi, K. (2004) Proteinase-activated receptor
2-mediated potentiation of transient receptor potential vanilloid subfam-
ily 1 activity reveals a mechanism for proteinase-induced inflammatory
pain. J. Neurosci. 24, 4293–4299
39. van der Merwe, J. Q., Ohland, C. L., Hirota, C. L., and MacNaughton,
W. K. (2009) Prostaglandin E2 derived from cyclooxygenases 1 and 2 me-
diates intestinal epithelial ion transport stimulated by the activation of
protease-activated receptor 2. J. Pharmacol. Exp. Ther. 329, 747–752
40. Camprubí-Robles, M., Planells-Cases, R., and Ferrer-Montiel, A. (2009)
Differential contribution of SNARE-dependent exocytosis to inflamma-
tory potentiation of TRPV1 in nociceptors. FASEB J. 23, 3722–3733
41. Rodrigo, R., Cauli, O., Gomez-Pinedo, U., Agusti, A., Hernandez-Rabaza,
V., Garcia-Verdugo, J. M., and Felipo, V. (2010) Hyperammonemia in-
duces neuroinflammation that contributes to cognitive impairment in rats
with hepatic encephalopathy. Gastroenterology 139, 675–684
42. Hasanein, P., Parviz, M., Keshavarz, M., Javanmardi, K., Allahtavakoli, M.,
and Ghaseminejad, M. (2007) Modulation of cholestasis-induced antino-
ciception in rats by two NMDA receptor antagonists: MK-801 and mag-
nesium sulfate. Eur. J. Pharmacol. 554, 123–127
43. Miura, T., Okazaki, R., Yoshida, H., Namba, H., Okai, H., and Kawamura,
M. (2005)Mechanisms of analgesic action of neurotropin on chronic pain
in adjuvant-induced arthritic rat: roles of descending noradrenergic and
serotonergic systems. J. Pharmacol. Sci. 97, 429–436
44. Banik, R. K., Sato, J., Yajima, H., and Mizumura, K. (2001) Differences
between the Lewis and Sprague-Dawley rats in chronic inflammation in-
duced norepinephrine sensitivity of cutaneous C-fiber nociceptors. Neu-
rosci. Lett. 299, 21–24
45. Twycross, R., Greaves,M.W., Handwerker, H., Jones, E. A., Libretto, S. E.,
Szepietowski, J. C., and Zylicz, Z. (2003) Itch: scratching more than the
surface. Qjm 96, 7–26
46. Clements, W. D., O’Rourke, D. M., Rowlands, B. J., and Ennis, M. (1994)
The role of mast cell activation in cholestatic pruritus. Agents Actions 41,
C30–31
47. Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M., Met-
tang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J.,
Davies, N. A., Rust, C., Engert, A., Jalan, R., Oude Elferink, R. P., and
Beuers, U. (2012) Serum autotaxin is increased in pruritus of cholestasis,
but not of other origin, and responds to therapeutic interventions. Hepa-
tology 56, 1391–1400
48. Hashimoto, T., Ohata, H., Momose, K., and Honda, K. (2005) Lysophos-
phatidic acid induces histamine release from mast cells and skin frag-
ments. Pharmacology 75, 13–20
49. Mela, M., Mancuso, A., and Burroughs, A. K. (2003) Review article: pru-
ritus in cholestatic and other liver diseases. Aliment Pharmacol. Ther. 17,
857–870
50. Mori, K., Kitayama, J., Aoki, J., Kishi, Y., Shida, D., Yamashita, H., Arai, H.,
andNagawa, H. (2007) Submucosal connective tissue-typemast cells con-
tribute to the production of lysophosphatidic acid (LPA) in the gastroin-
testinal tract through the secretion of autotaxin (ATX)/lysophospholipase
D (lysoPLD). Virchows Archiv. 451, 47–56
51. Steinhoff, M., Buddenkotte, J., Shpacovitch, V., Rattenholl, A., Moor-
mann, C., Vergnolle, N., Luger, T. A., and Hollenberg, M. D. (2005) Pro-
TRPV1 in Cholestatic Pruritus
9684 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 14•APRIL 5, 2013
teinase-activated receptors: transducers of proteinase-mediated signaling
in inflammation and immune response. Endocrine Rev. 26, 1–43
52. Amaya, F., Oh-hashi, K., Naruse, Y., Iijima, N., Ueda, M., Shimosato, G.,
Tominaga, M., Tanaka, Y., and Tanaka, M. (2003) Local inflammation
increases vanilloid receptor 1 expression within distinct subgroups of
DRG neurons. Brain Res. 963, 190–196
53. Yu, L., Yang, F., Luo, H., Liu, F. Y., Han, J. S., Xing, G. G., and Wan, Y.
(2008) The role of TRPV1 in different subtypes of dorsal root ganglion
neurons in rat chronic inflammatory nociception induced by complete
Freund’s adjuvant.Mol. Pain 4, 61
54. Ui, H., Andoh, T., Lee, J. B., Nojima, H., and Kuraishi, Y. (2006) Potent
pruritogenic action of tryptasemediated by PAR2 receptor and its involve-
ment in anti-pruritic effect of nafamostat mesilate in mice. Eur. J. Phar-
macol. 530, 172–178
55. Reddy, V. B., Iuga, A. O., Shimada, S. G., LaMotte, R. H., and Lerner, E. A.
(2008) Cowhage-evoked itch is mediated by a novel cysteine protease: a
ligand of protease-activated receptors. J. Neurosci. 28, 4331–4335
56. Yosipovitch, G., and Papoiu, A. D. (2008) What causes itch in atopic der-
matitis? Curr. Allergy Asthma Rep. 8, 306–311
57. Briot, A., Deraison, C., Lacroix, M., Bonnart, C., Robin, A., Besson, C.,
Dubus, P., and Hovnanian, A. (2009) Kallikrein 5 induces atopic der-
matitis-like lesions through PAR2-mediated thymic stromal lympho-
poietin expression in Netherton syndrome. J. Exp. Med. 206,
1135–1147
TRPV1 in Cholestatic Pruritus
APRIL 5, 2013•VOLUME 288•NUMBER 14 JOURNAL OF BIOLOGICAL CHEMISTRY 9685
